9999999997-12-013117.txt : 20120831 9999999997-12-013117.hdr.sgml : 20120831 20120831125314 ACCESSION NUMBER: 9999999997-12-013117 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120831 DATE AS OF CHANGE: 20120831 20120830 20120831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPTIMER PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001142576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330830300 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-33291 FILM NUMBER: 121067850 BUSINESS ADDRESS: STREET 1: 10110 SORRENTO VALLEY ROAD STREET 2: SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8589090736 MAIL ADDRESS: STREET 1: 10110 SORRENTO VALLEY ROAD STREET 2: SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.;094P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^2XI&7UX M#2G3PXNV66?&+MGB9L9R<["K\1C#ORS@ARX[@Y]SE3KJUJ2TDJ6#7>O_1%-N=)9Z$+ZDODV\3W6MU)?J$[*?Y# M=^=%9M/^FA\IS>CNHA3?FI\U,-\B5.@[W6^BP?>:FV\R+E4-VA M=2HZ\AKJCA1]R=MUBI7E`',<_!V5^$N``0!J2H@B#0IE;F1S=')E86T-96YD M;V)J#3$T(#`@;V)J#3P\+T9I;'1E4M"_M%>YQ^P`\;PQ'AM6$[((CK116 M*V,:Z)5C,SXFDW^_U9\\'# M/WS$'@R]$1V%D#SW/#C@?Y+)KY<>`2?YK\=&X#+*(DBFYB3YW2S<@,;Q^=:E MGL=BJ6X6+[TG\KA<)#/'#6E,IK!VW(@.2>)01L:)/IV90W#^2?[HN0,Z'$;7 M-KV!L2D7TN9Z-GE<+9*%@](A&H#Q<@KH)*`#\O?DZWAY9S8P>;B_7ZS7BX>E M-C^DP>#&.+/&F>&/6XN`9'!Y6 MT]D*[AQWA+FOQLMDL;S#\)9S%1=:"$,LB-7VC7;D:^W%=(8:XV^0K&;CY!XW M!BY4'$07L1EEC;STF'R=@<4+D9H9?&`\2>!A#BP.)/P^"8U!+$7X0:Z,T="_ M=A=($=>L5*JG1CSS"OX\.@,:D;1Z3C/>-B)+\[H/BR*C3D0#4W"4&'T`[>`* M63(7.8=E28&Y0>#'#%R8S'_S1P/DKY2GPPL^DG_?^R@Y[(10=X)$T!`N/%/< MNTYQ:%-D)D5P7'\8>4@QE:PSPCQ5QIBLVIPS=B3)^XYDN$P=ZG:K1433\!VD M!:2GDR,[($?Y1I0%M,4.C:U:S-4/MZZOD<*VD[%$'=R1CJ7BWUM>-Z(X0%86 M>['C12/2')J*IXUT%1#NN&B_:&!?5B`*_-;GZ$[3;T0':,ZS^8ZL#T,EC$DT MP']F>;O#F/=5*?6QOYHCA]G/H]B*IH:FA!3FSI"4#AV1RH@8GFH/5ZBR+A/= M>LQS_X(]5G@'Z-`VHNY#:B?/+4-^A8JI$/F2UMI>Q4\5KQ$;A3$"'I$:MJ]@ M"QA<%C#H"HCE"TGN8.!#HMBK-+&.S3%M\$MM17V#*OJ[K%EHH\,FEY%_;]-< M[`6O(:VOBY:5S]@ZF5QBJ?9"]1Q.N4%T,1U"G6*1%DI0N9:S<$!D`#ZY9)&L MT+SB?%?J.RCWMB3:;%<2G#(V!V9,C+.F#Q$\TC6=4(@B?T.V&V=#PHW35Y:G MXD?'(-^$>*[0$ZFE%?0X*:M366FC\X>AQB'P1!=:I(XL?O3>F M7=.,"&%1-I)PIW:+;9._PD[465[6'(E*`0//RFJ'+9$K`",Y]CMVO^'*:__, M[3=U-&0/--GW99Z7+[+73*C1U1M%CH@N4F;,<]T@&U*KN;=QL!MC`B\BST&F ML<4QR52/,H(T50,CUP]%7DQ3NCXI,94O[/&689^A7R)K;"Q(%=!TC@EJ\$J4 M.W6'SC<.U"]`?V; M>N">ZKTY7LG'A78A]S@GK=E2BSW+Q]!8DW6SE+%QC)4=5.@TNX60"ZG;G33V MY-9M=V&BFUJK0B^Z[+A5S.RB4RVU*2D8R9\7!E+UA-3"]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME="!B96=I M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E M(%A-4"!#;W)E(#4N,BUC,#`Q(#8S+C$S.30S.2P@,C`Q,"\P.2\R-RTQ,SHS M-SHR-B`@("`@("`@(CX*("`@/')D9CI21$8@>&UL;G,Z&UL M;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(^36EC&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N M8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0&UP34TZ26YS M=&%N8V5)1#YU=6ED.CAC-#,P,V8U+61C9F$M-#(V92TX-F%F+61B-3&UP34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I M;VX^"B`@(#POJ'5!:DZ@L M=[L<\!EA1#*0@BZ/92YVML2;YBO``)0)0!$-"F5N9'-TF4@ M,3`O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F(``B9&KC,,3`R, M;4""+PK$Z@41;$")IX>`+`8&1B#!]!](,#(`!!@`>/8%&PT*96YD